Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trialGilbert Bensimon, Massimo Locati, S. Beltran et al.|The Lancet|2025Cited by 33
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis opticaÉdouard Januel, Pierre Labauge, Céline Louapre et al.|Multiple Sclerosis Journal|2021Cited by 18